Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPKAPK2 | P49137 | 5/20 | 0.36 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.35 |
| ▸ | STK17B | O94768 | 1/20 | 0.34 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.34 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | SYK | P43405 | 1/20 | 0.32 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.32 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.32 |
| ▸ | ATR | Q13535 | 1/20 | 0.32 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.31 |
| ▸ | BACE1 | P56817 | 1/20 | 0.31 |
| ▸ | GBA1 | P04062 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29837499 | 1.00 | MAPKAPK2 (0.36) | MAPKAPK2PDPK1STK17BSTK17ASSTR4 | |
| SCHEMBL26662783 | 0.87 | PDPK1 (0.33) | PDPK1SSTR4USP30BACE1 | |
| SCHEMBL29512299 | 0.87 | PDPK1 (0.33) | PDPK1SSTR4USP30BACE1 | |
| SCHEMBL26975107 | 0.84 | MAPKAPK2 (0.36) | MAPKAPK2PDPK1STK17BSTK17ALMNA | |
| SCHEMBL26646973 | 0.81 | CCR4 (0.36) | MAPKAPK2PDPK1STK17BSTK17ALMNA | |
| SCHEMBL30068021 | 0.81 | CCR4 (0.36) | MAPKAPK2PDPK1STK17BSTK17ALMNA | |
| SCHEMBL25351955 | 0.80 | SSTR4 (0.32) | PDPK1SSTR4USP30BACE1 | |
| SCHEMBL30550888 | 0.80 | NFKB1 (0.35) | MAPKAPK2PDPK1STK17BSTK17ALMNA | |
| SCHEMBL2386488 | 0.79 | SSTR4 (0.34) | PDPK1SSTR4USP30AAK1BACE1 | |
| SCHEMBL22958315 | 0.78 | PDPK1 (0.34) | MAPKAPK2PDPK1STK17BSTK17ASSTR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12331056-B2 | SHP2 phosphatase inhibitors and methods of use thereof | RELAY THERAPEUTICS, INC. (US) | 2025-06-17 | — | — | US | disclosed |
| EP-4506035-A2 | SHP2 PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | Relay Therapeutics, Inc. (US) | 2025-02-12 | — | — | EP | disclosed |
| US-12084447-B2 | SHP2 phosphatase inhibitors and methods of use thereof | RELAY THERAPEUTICS, INC. (US) | 2024-09-10 | — | — | US | disclosed |
| EP-3768668-B1 | SHP2 PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS INC (US) | 2024-08-28 | — | — | EP | disclosed |
| US-20240083897-A1 | GCN2 MODULATING COMPOUNDS AND USES THEREOF | HIBERCELL, INC. | 2024-03-14 | — | — | US | disclosed |
| EP-4328228-A1 | HETEROCYCLIC COMPOUND FOR INHIBITING SHP2 ACTIVITY, PREPARATION METHOD THEREFOR AND USE THEREOF | Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) | 2024-02-28 | — | — | EP | disclosed |
| CN-117263942-A | SHP2 phosphatase inhibitors and methods of use thereof | 传达治疗有限公司 | 2023-12-22 | — | — | CN | disclosed |
| CN-117203206-A | GCN2 modulating compounds and uses thereof | 希伯塞尔股份有限公司 | 2023-12-08 | — | — | CN | disclosed |
| EP-4281182-A1 | GCN2 MODULATING COMPOUNDS AND USES THEREOF | Hibercell, Inc. (US) | 2023-11-29 | — | — | EP | disclosed |
| CN-112166110-B | SHP2 phosphatase inhibitors and methods of use thereof | 传达治疗有限公司 | 2023-08-11 | — | — | CN | disclosed |
| US-20220340576-A1 | SHP2 PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS, INC. | 2022-10-27 | — | — | US | disclosed |
| US-20220315586-A1 | SHP2 PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | SCHRODINGER, INC. | 2022-10-06 | — | — | US | disclosed |
| US-10934302-B1 | SHP2 phosphatase inhibitors and methods of use thereof | RELAY THERAPEUTICS, INC. (US) | 2021-03-02 | — | — | US | disclosed |
| CN-112166110-A | SHP2 phosphatase inhibitors and methods of use thereof | 传达治疗有限公司 | 2021-01-01 | — | — | CN | disclosed |
| US-20180065949-A1 | 1-(TRIAZIN-3-YL/PYRIDAZIN-3-YL)-PIPER(-AZINE)IDINE DERIVATIVES AND COMPOSITIONS THEREFOR FOR INHIBITING THE ACTIVITY OF SHP2 | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. | 2018-03-08 | — | — | US | disclosed |
| US-9815813-B2 | 1-(triazin-3-yl/pyridazin-3-yl)-piper(-azine)idine derivatives and compositions therefor for inhibiting the activity of SHP2 | NOVARTIS AG (CH) | 2017-11-14 | — | — | US | disclosed |
| US-20170204080-A1 | 1-PYRIDAZIN-/TRIAZIN-3-YL-PIPER(-AZINE)/IDINE/PYROLIDINE DERIVATIVES AND COMPOSITIONS THEREOF FOR INHIBITING THE ACTIVITY OF SHP2 | NOVARTIS AG (CH) | 2017-07-20 | — | — | US | disclosed |
| US-20170001975-A1 | 1-(TRIAZIN-3-YL/PYRIDAZIN-3-YL)-PIPER(-AZINE)IDINE DERIVATIVES AND COMPOSITIONS THEREFOR FOR INHIBITING THE ACTIVITY OF SHP2 | NOVARTIS AG (CH) | 2017-01-05 | — | — | US | disclosed |
| WO-2015107493-A1 | 1 -PYRIDAZIN-/TRIAZIN-3-YL-PIPER(-AZINE)/IDINE/PYROLIDINE DERIVATIVES AND AND COMPOSITIONS THEREOF FOR INHIBITING THE ACTIVITY OF SHP2 | NOVARTIS AG (CH) | 2015-07-23 | — | — | WO | disclosed |
| WO-2015107494-A1 | 1 -(TRIAZIN-3-YI_/PYRIDAZIN-3-YL)-PIPER(-AZINE)IDINE DERIVATIVES AND COMPOSITIONS THEREOF FOR INHIBITING THE ACTIVITY OF SHP2 | NOVARTIS AG (CH) | 2015-07-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220340576-A1 | SHP2 PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | PTPRCAP, PTPN22, PTPN1 | MAPKAPK2 191/4885PDPK1 287/4885STK17B 591/4885 |
| US-12084447-B2 | SHP2 phosphatase inhibitors and methods of use thereof | PTPRCAP, PTPN22, PTPN1 | MAPKAPK2 191/4885PDPK1 287/4885STK17B 591/4885 |
| US-20240083897-A1 | GCN2 MODULATING COMPOUNDS AND USES THEREOF | EIF2AK4, GCN1, CLN6 | MAPKAPK2 330/4885PDPK1 563/4885STK17B 2623/4885 |
| US-20170001975-A1 | 1-(TRIAZIN-3-YL/PYRIDAZIN-3-YL)-PIPER(-AZINE)IDINE DERIVATIVES AND COMPOSITIONS THEREFOR FOR INHIBITING THE ACTIVITY OF SHP2 | PTPN1, PTPN5, PTPN7 | MAPKAPK2 342/4885PDPK1 225/4885STK17B 165/4885 |
| US-10934302-B1 | SHP2 phosphatase inhibitors and methods of use thereof | PTPRCAP, PTPRJ, PTPRC | MAPKAPK2 241/4885PDPK1 230/4885STK17B 637/4885 |
| US-20220315586-A1 | SHP2 PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | PTPRCAP, PTPN22, PTPN1 | MAPKAPK2 191/4885PDPK1 287/4885STK17B 591/4885 |
| US-20170204080-A1 | 1-PYRIDAZIN-/TRIAZIN-3-YL-PIPER(-AZINE)/IDINE/PYROLIDINE DERIVATIVES AND COMPOSITIONS THEREOF FOR INHIBITING THE ACTIVITY OF SHP2 | PTPN5, PTPN1, PTPN2 | MAPKAPK2 387/4885PDPK1 281/4885STK17B 330/4885 |
| US-12331056-B2 | SHP2 phosphatase inhibitors and methods of use thereof | PTPRCAP, PTPN22, PTPN1 | MAPKAPK2 191/4885PDPK1 287/4885STK17B 591/4885 |
| US-20180065949-A1 | 1-(TRIAZIN-3-YL/PYRIDAZIN-3-YL)-PIPER(-AZINE)IDINE DERIVATIVES AND COMPOSITIONS THEREFOR FOR INHIBITING THE ACTIVITY OF SHP2 | PTPN1, PTPN5, PTPN7 | MAPKAPK2 342/4885PDPK1 225/4885STK17B 165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.